Oropharyngeal cancer – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:15:20 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Oropharyngeal cancer – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Electrochemotherapy with Bleomycin for Patients with Recurrent Oral and Oropharyngeal Cancer https://clinicaltrials.eu/trial/study-on-electrochemotherapy-with-bleomycin-for-patients-with-recurrent-oral-and-oropharyngeal-cancer/ Wed, 29 Apr 2026 15:04:07 +0000 https://clinicaltrials.eu/trial/study-on-electrochemotherapy-with-bleomycin-for-patients-with-recurrent-oral-and-oropharyngeal-cancer/ This clinical trial is focused on studying a treatment for squamous cell carcinoma of the oral cavity and oropharynx, which are areas in the mouth and throat. The study is investigating the effectiveness of a treatment called electrochemotherapy, which combines the use of electrical impulses with a drug called bleomycin. This treatment will be compared to a combination of other medications, including cetuximab, platinum-based therapy (such as carboplatin or cisplatin), and 5-fluorouracil.

The purpose of the study is to determine if electrochemotherapy with bleomycin is more effective in treating the cancer compared to the other combination of drugs. Participants in the study will receive either the electrochemotherapy treatment or the combination of cetuximab, platinum-based therapy, and 5-fluorouracil. The study will monitor the response of the cancer to these treatments, as well as overall survival, the time the disease remains under control, and the quality of life of the participants.

Throughout the study, participants will receive their assigned treatment and be regularly assessed to track the progress of their cancer and any side effects they may experience. The study aims to provide valuable information on the best treatment options for patients with recurrent squamous cell carcinoma of the oral cavity and oropharynx.

]]> Study of Cisplatin, Carboplatin and Durvalumab Treatment for Patients with Intermediate and High-Risk Oropharyngeal Cancer https://clinicaltrials.eu/trial/study-on-treatment-options-for-intermediate-and-high-risk-oropharyngeal-cancer-using-cisplatin-carboplatin-and-durvalumab/ Wed, 29 Apr 2026 14:58:29 +0000 https://clinicaltrials.eu/trial/study-on-treatment-options-for-intermediate-and-high-risk-oropharyngeal-cancer-using-cisplatin-carboplatin-and-durvalumab/ This clinical trial focuses on oropharyngeal cancer, which is a type of cancer that affects the middle part of the throat, including the base of the tongue and tonsils. The study aims to compare different treatment approaches to improve survival rates in patients with intermediate and high-risk forms of this disease.

The treatment combines several medications given through intravenous infusion. These include cisplatin and carboplatin, which are chemotherapy drugs that help fight cancer cells, along with durvalumab, which is a type of medication that helps the body’s immune system detect and fight cancer cells. These medications will be given together with radiation therapy, which uses high-energy rays to target cancer cells.

The study will monitor how well patients respond to the treatment combinations by tracking their overall health, quality of life, and ability to swallow. The treatment schedule includes regular visits to receive the medications and check-ups to monitor the patient’s progress. Throughout the study, doctors will carefully watch for and manage any side effects that may occur from the treatment.

]]> Study on Swallowing and Quality of Life in Advanced Head and Neck Cancer Patients Using Cisplatin and Drug Combination https://clinicaltrials.eu/trial/study-on-swallowing-and-quality-of-life-in-advanced-head-and-neck-cancer-patients-using-cisplatin-and-drug-combination/ Wed, 29 Apr 2026 14:23:42 +0000 https://clinicaltrials.eu/trial/study-on-swallowing-and-quality-of-life-in-advanced-head-and-neck-cancer-patients-using-cisplatin-and-drug-combination/ This clinical trial focuses on patients with advanced head and neck cancer, specifically those with oropharyngeal cancer. The study aims to understand how different approaches to feeding tube placement affect patients’ ability to swallow and their overall quality of life after receiving a combination of chemotherapy and radiation therapy. The chemotherapy treatment involves the use of cisplatin, a medication given through an injection into a vein. The study will compare two groups of patients: one group will receive a feeding tube before starting treatment (prophylactic), and the other group will receive a feeding tube only if it becomes necessary during treatment (reactive).

In addition to cisplatin, the study involves the use of iomeprol, barium sulfate, and fludeoxyglucose (18F). Iomeprol and fludeoxyglucose (18F) are solutions for injection, while barium sulfate is taken orally. These substances are used to help visualize the body during imaging tests, which are part of the study’s assessments. The purpose of the study is to evaluate patient-reported outcomes, such as swallowing ability and quality of life, six months after completing treatment. This will help determine the best approach to managing feeding needs in patients undergoing treatment for head and neck cancer.

Participants in the study will be monitored over a period of time, with regular assessments to track their progress and any side effects they may experience. The study will also collect information on the impact of treatment on patients’ nutritional status and overall health. By comparing the two groups, researchers hope to find the most effective way to support patients’ nutritional needs and improve their quality of life during and after cancer treatment.

]]>